Open AccessAssociation of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non–Small Cell Lung Cancer
Author(s) -
Yunfang Yu,
Dongqiang Zeng,
Qiyun Ou,
Shengbo Liu,
Anlin Li,
Yongjian Chen,
Dagui Lin,
Quanlong Gao,
Haiyu Zhou,
Wangjun Liao,
Herui Yao
Publication year - 2019
Publication title -
jama network open
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.278
H-Index - 39
ISSN - 2574-3805
DOI - 10.1001/jamanetworkopen.2019.6879
Subject(s) - medicine , immunotherapy , oncology , lung cancer , hazard ratio , clinical trial , cancer , confidence interval
This meta-analysis examines whether differences in biomarkers, such as programmed cell death ligand 1 (PD-L1) expression and tumor mutation burden, are associated with improved response to immunotherapy and survival in patients with advanced non–small cell lung cancer (NSCLC).
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom